Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7513)
All Articles published online
|
Publishing Process of This Article
|
Sep 7, 2019 (publication date) through Nov 22, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019; 25(33): 4985-4998 [PMID: 31543688 DOI: 10.3748/wjg.v25.i33.4985] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v25/i33/4985.htm |
| Number | Citing Articles |
| 1 |
Dong Hyun Kim, Yu-Min Choi, Junghwa Jang, Bum-Joon Kim. Global prevalence and molecular characteristics of three clades within hepatitis B virus subgenotype C2: Predominance of the C2(3) clade in South Korea. Frontiers in Microbiology 2023; 14 doi: 10.3389/fmicb.2023.1137084
|
| 2 |
Manas K. Behera, Girish K. Pati, Jimmy Narayan, Debakanta Mishra, Lalit K. Meher, Ayaskant Singh, Kanishka Uthansingh, Manoj K. Sahu. Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen–Positive Chronic Hepatitis B. Journal of Clinical and Experimental Hepatology 2021; 11(1): 37 doi: 10.1016/j.jceh.2020.05.003
|